Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human U2AF35 aa 150 to the C-terminus (Cysteine residue). The exact sequence is proprietary.
Database link: Q01081
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
This product is a recombinant rabbit monoclonal antibody.
Our Abpromise guarantee covers the use of ab172614 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/5000. Detects a band of approximately 35 kDa (predicted molecular weight: 28 kDa).|
|IHC-P||1/50 - 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
|ICC/IF||1/50 - 1/100.|
|IP||1/10 - 1/100.|
Immunohistochemical analysis of paraffin-embedded Human pancreas tissue labeling U2AF35 with ab172614 at 1/50 dilution.
Immunohistochemical analysis of paraffin-embedded Human endometrial carcinoma tissue labeling U2AF35 with ab172614 at 1/50 dilution.
Immunofluorescent analysis of HeLa cells labeling U2AF35 with ab172614 at 1/50 dilution.
Western blot analysis on immunoprecipitation pellet from HeLa cell lysate immunoprecipitated using ab172614 at 1/10 dilution.
ab172614 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"